Patient-reported pain severity, pain interference and health status in HR+/HER2-advanced/metastatic breast cancer

ESMO Open

Volumn 2, Issue 3, 2017, Pages

  Wood, Robert ^a   Mitra, Debanjali ^b   De Courcy, Jonathan ^a   Iyer, Shrividya ^b  

^a ADELPHI REAL WORLD   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

Advanced Breast Cancer; Brief Pain Inventory; Eq 5d; Metastatic Breast Cancer; Real world

Indexed keywords

EID: 85052610795     PISSN: None     EISSN: 20597029     Source Type: Journal    
DOI: 10.1136/esmoopen-2017-000227     Document Type: Article

References (25)

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-E386.
2. International Agency for Research on Cancer and World Health Organization. GLOBOCAN. Estimated cancer incidence, mortality and prevalence worldwide 2012. http://globocan.iarc.fr/Default.aspx (accessed Nov 1 2016).
3. Maclean R, Jeffreys M, Ives A, et al. Primary care characteristics and stage of cancer at diagnosis using data from the national cancer registration service, quality outcomes framework and general practice information. BMC Cancer 2015;15:500.
4. Ginsburg OM, Fischer HD, Shah BR, et al. A population-based study of ethnicity and breast cancer stage at diagnosis in Ontario. Curr Oncol 2015;22:97-104.
5. Walters S, Maringe C, Butler J, et al. Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study. Br J Cancer 2013;108:1195-208.
6. Lobbezoo DJ, van Kampen RJ, Voogd AC, et al. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat 2013;141:507-14.
7. Rugo HS, Rumble RB, Macrae E, et al. Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. J Clin Oncol 2016;34:3069-103.
8. Cardoso F, Costa A, Senkus E, et al. European School of Oncology; European Society of Medical Oncology. ESO-ESMO 3rd international consensus guidelines for advanced breast cancer (ABC 3). Breast 2017;31:244-59.
9. Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007;25:3877-83.
10. Henry NL, Azzouz F, Desta Z, et al. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 2012;30:936-42.
11. Clinic M. Chemotherapy for breast cancer. 2016. http://www. mayoclinic.org/tests-procedures/chemotherapy-for-breast-cancer/details/risks/cmc-20253603 (accessed Nov 1 2016).
12. Anderson P, Benford M, Harris N, et al. Real-world physician and patient behaviour across countries: Disease-Specifc Programmes-a means to understand. Curr Med Res Opin 2008;24:3063-72.
13. Smyth EN, Shen W, Bowman L, et al. Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer. Health Qual Life Outcomes 2016;14:1-10.
14. Cleeland CS, Body J-J, Stopeck A, et al. Pain outcomes in patients with advanced breast cancer and bone metastases. Cancer 2013;119:832-8.
15. Spiegel D, Bloom JR. Pain in metastatic breast cancer. Cancer 1983;52:341-5.
16. Chow E, Hird A, Velikova G, et al. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with bone metastases: the EORTC QLQ-BM22. Eur J Cancer 2009;45:1146-52.
17. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129-38.
18. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337-43.
19. Szende A, Oppe M, Devlin N. EQ-5D Value Sets: Inventory, Comparative Review and User Guide. The Netherlands: Springer, 2007.
20. Serlin RC, Mendoza TR, Nakamura Y, et al. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995;61:277-84.
21. StataCorp. Stata Statistical Software: Release 14. College Station, TX: StataCorp, 2015.
22. Kind P, Hardman G, Macran S. UK Population Norms for EQ-5D, 1999. The University of York Centre for Health Economics Discussion Paper 172.
23. Wallwiener M, Simoes E, Sokolov AN, et al. Health-related Quality of Life in Metastatic and Adjuvant Breast Cancer Patients. Geburtshilfe Frauenheilkd 2016;76:1065-73.
24. Badger T, Segrin C, Dorros SM, et al. Depression and anxiety in women with breast cancer and their partners. Nurs Res 2007;56:44-53.
25. Hwang SY, Chang SJ, Park BW. Does chemotherapy really affect the quality of life of women with breast cancer? J Breast Cancer 2013;16:229-35.